Mihael Hristos Polymeropoulos Acquires 20,000 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos acquired 20,000 shares of the firm’s stock in a transaction dated Friday, May 16th. The shares were bought at an average cost of $4.22 per share, with a total value of $84,400.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,315,731 shares of the company’s stock, valued at $9,772,384.82. The trade was a 0.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Wednesday, March 5th, Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock. The shares were bought at an average cost of $5.02 per share, with a total value of $50,200.00.
• On Friday, February 28th, Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock. The shares were bought at an average cost of $4.76 per share, with a total value of $47,600.00.
• On Tuesday, February 25th, Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock. The shares were bought at an average cost of $4.46 per share, with a total value of $44,600.00.

Vanda Pharmaceuticals Price Performance

VNDA opened at $4.44 on Wednesday. The firm has a market cap of $261.67 million, a P/E ratio of -13.88 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a 1-year low of $3.81 and a 1-year high of $6.75. The company has a 50 day simple moving average of $4.42 and a two-hundred day simple moving average of $4.63.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.05. The business had revenue of $50.04 million during the quarter, compared to analyst estimates of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. Equities analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Quantinno Capital Management LP bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth $48,000. Linden Thomas Advisory Services LLC bought a new position in shares of Vanda Pharmaceuticals during the first quarter worth $49,000. Nations Financial Group Inc. IA ADV bought a new position in shares of Vanda Pharmaceuticals during the first quarter worth $67,000. XTX Topco Ltd bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth $69,000. Finally, Virtu Financial LLC bought a new position in shares of Vanda Pharmaceuticals during the first quarter worth $72,000. 88.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

VNDA has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. Finally, StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a “hold” rating for the company.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.